Giant cell arteritis.
OBJECTIVE
Giant cell arteritis is an important cause of blindness in patients over 60 years of age. We attempt to identify the important clinical aspects in the diagnosis and management of this disorder, so that treatment may be instituted expeditiously to limit visual loss.


RESULTS
In addition, we identify current areas of standards in the investigation and treatment of patients with suspected giant cell arteritis.


CONCLUSIONS
We review some newer treatment possibilities, based on recently proposed immunologic models of giant cell arteritis, that may lead to newer treatment modalities.
Danesh-Meyer
Helen V
HV
Department of Ophthalmology, University of Auckland, Auckland, New Zealand.
Savino
Peter J
PJ
D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D004334:Drug Administration Schedule; D013700:Giant Cell Arteritis / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011379:Prognosis; D014786:Vision Disorders / Q000209:etiology
D000305:Adrenal Cortex Hormones; D010975:Platelet Aggregation Inhibitors; D008775:Methylprednisolone; D008727:Methotrexate